Skip to content
Open access

Preparing for Next-Generation Vaccines: Breakthrough Invasive Pneumococcal Disease Patterns Post-PCV13 and Post-PPSV23 in Australia.

Oct 2026 · International Journal of Infectious Diseases · pp. 109215 · 0 citations · 24 references
Medicine

TL;DR

Serotype 3, included in all current conjugate formulations, dominated breakthrough for both vaccines, and in descriptive comparisons limited by small subgroup sizes, neither additional doses nor sequential vaccination was associated with lower vaccine-type proportions.

Abstract

Background

Pneumococcal conjugate (PCV) and polysaccharide (PPSV) vaccines have reduced invasive pneumococcal disease (IPD) in Australia. We evaluated breakthrough IPD following PCV13 and PPSV23 immunization (2009-2023) to inform next-generation vaccine strategies.

Methods

We analyzed laboratory-confirmed IPD cases from the National Notifiable Diseases Surveillance System to estimate the vaccine-type proportion among vaccinated IPD cases (those meeting the minimum age-specific dose threshold), whose vaccine-type infections constitute breakthrough IPD. Temporal trends were assessed using logistic regression, and subgroup differences using chi-square or Fisher's tests. Random Forest and Gradient Boosting models with five-fold cross-validation classified IPD due to PPSV23-type serotypes.

Results

Across 25,643 IPD cases, annual notifications increased while PCV13-type proportions declined. PCV13-type proportions were 19.4% in infants and 37.5% at 2-14 years; PPSV23-type proportions were 47.5% at 15-69 and 48.4% at ≥70 years, with serotype 3 the largest contributor. Vaccinated individuals showed lower vaccine-type proportions than non- or partially vaccinated cases across age groups. Vaccine-type proportions were highest for pneumonia and in the Northern Territory, with greatest residual burden among older adults and Indigenous Australians. Machine-learning models classifying PPSV23-type IPD (accuracy ≈92%) identified vaccination-related variables, clinical presentation, and year of infection as key predictors; excluding these variables reduced AUC from 0.97-0.98 to 0.69.

Conclusion

PCV13-type proportions declined over time, most markedly in infants, whereas PPSV23-type proportions remained persistently high in older adults and Indigenous Australians despite higher documented vaccination. Serotype 3, included in all current conjugate formulations, dominated breakthrough for both vaccines, and in descriptive comparisons limited by small subgroup sizes, neither additional doses nor sequential vaccination was associated with lower vaccine-type proportions.

Read PDF

Similar papers

Open access Oct 2026

Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease in Canada: A Canadian Immunization Research Network (CIRN) study

Abstract The effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) to prevent vaccine-serotype (VT) invasive pneumococcal disease (IPD) in children aged 2–59 months was assessed using data from 4 geographically defined areas in Canada with IPD surveillance, including immunization status. VT IPD cases an...

G. Deceuninck, N. Brousseau, Allison McGeer et al. · 0 citations
Open access Sep 2026

Estimation of preventable pneumococcal disease burden by PCV20 or PCV21 under the national immunization program for adults aged 65 years in Japan

The data indicate that PCV21 could prevent 1.5-1.7 times as many pneumococcal disease cases as PCV20 among adults aged [≥] 65 years in Japan, however, PCV20 should be considered if the incidence of adult IPD cases caused by PCV20-non-PCV21 serotypes increases.

K. Tamura, B. Chang, R. Shimbashi et al. · 0 citations
Review Nov 2026

Pneumococcal vaccination for prevention of infection and diagnosis of antibody deficiency in the extended conjugated vaccine era.

PURPOSE OF REVIEW Pneumococcal conjugate vaccines (PCV) have transformed pneumococcal disease prevention. Recent expansion to higher-valency formulations (PCV15, PCV20, PCV21) and updated Advisory Committee on Immunization Practices (ACIP) recommendations extending coverage to all healthy PCV-naïve adults ≥50 years in...

Mohamad Shieb, Gu-Yu Li, A. Joshi · 0 citations
Open access Oct 2026

Simplifying Adult Pneumococcal Vaccination in India: A Cost-Effectiveness Analysis of the 20-Valent Conjugate Vaccine.

INTRODUCTION In India, adult pneumococcal disease prevention relies on the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) and the 13‑ and 20‑valent pneumococcal conjugate vaccines (PCV13, PCV20). Before PCV20 introduction, adults at older age or high risk typically received PCV13 followed by PPSV23, although no...

S. Taur, N. Kulkarni, Sachin Choudhari et al. · 0 citations
Open access Oct 2026

The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study

Introduction: This study compared the health and economic impact of the 21-valent pneumococcal conjugate vaccine (aPCV21) vs the 20-valent pneumococcal conjugate vaccine (PCV20) on invasive pneumococcal disease (IPD) and post-meningitis sequelae (PMS) among adults aged 65 years and older in the United Kingdom (UK). Met...

P. Mueller, M. Simuzingili, I. Matthews et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.